The longevity community has been buzzing about psilocybin's life-extending properties in mice, but new mortality data suggests the hype may be premature for humans. This reality check comes at a crucial time when psychedelic research is experiencing unprecedented investment and clinical interest. Researchers tracked mortality patterns among 11 prominent psychedelic advocates and researchers known to use these substances, comparing them against 12 cancer researchers and 5 aging specialists as control groups. While all three cohorts lived longer than general population averages—reflecting the typical longevity advantage of educated, affluent professionals—the psychedelic users showed no mortality benefit compared to their scientific peers. The psychedelic group's lifespan matched that of cancer and aging researchers who presumably did not use these compounds regularly. This finding is particularly striking given that many psychedelic advocates have used these substances for decades, providing a reasonable observational window for potential longevity effects. The study represents one of the first attempts to bridge the gap between promising preclinical data and real-world human outcomes in psychedelic longevity research. However, significant limitations constrain interpretation: the sample size is extremely small, the cohort is highly educated and socioeconomically advantaged, and lifestyle factors beyond psychedelic use weren't controlled. The researchers wisely emphasize that rigorous mechanistic studies and larger epidemiological investigations are essential before drawing conclusions about human anti-aging effects. This work serves as a valuable reminder that promising animal longevity findings often fail to translate directly to human populations, particularly in the complex, multi-factorial realm of aging research.